Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3091205 | 0.95 | ALDH1A1 (0.59) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL20390809 | 0.85 | ALDH1A1 (0.69) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL28109027 | 0.83 | ALDH1A1 (0.61) | ALDH1A1PKMSMN1; SMN2CA1CA2 | |
| SCHEMBL25379509 | 0.83 | ALDH1A1 (0.49) | ALDH1A1PKMSMN1; SMN2MMP1MMP2 | |
| SCHEMBL28400660 | 0.82 | MMP2 (0.57) | ALDH1A1SMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL25431630 | 0.82 | FFAR4 (0.51) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL5563528 | 0.82 | ALDH1A1 (0.86) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL1619896 | 0.80 | ALDH1A1 (0.71) | ALDH1A1PKMSMN1; SMN2CYP19A1CA1 | |
| SCHEMBL2624207 | 0.80 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2CYP19A1CA1CA2 | |
| SCHEMBL3094703 | 0.80 | ALDH1A1 (0.56) | ALDH1A1PKMSMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106008288-A | Benzsulfamide compound and application thereof | 西北农林科技大学 | 2016-10-12 | — | — | CN | claimed |
| EP-0929519-B1 | BETA-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2005-02-23 | — | — | EP | claimed |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| EP-4486452-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LASSS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023166039-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166039-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-09-07 | — | — | WO | disclosed |
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-1628957-B1 | SULFOPYRROLES | TAKEDA PHARMACEUTICAL (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-7612064-B2 | Sulfopyrroles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070060570-A1 | Sulfopyrroles | TALEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1655284-A1 | 2-Phenylsulfopyrroles | Aponetics AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1628957-A1 | SULFOPYRROLES | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004103968-A1 | SULFOPYRROLES | APONETICS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060570-A1 | Sulfopyrroles | TYK2, ARSA, SULT2A1 | ALDH1A1 1078/4885PKM 1217/4885SMN1; SMN2 2378/4885 |
| US-20250170104-A1 | INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR Lasß | LTA, SERPINB1, LAS1L | ALDH1A1 3061/4885PKM 3730/4885SMN1; SMN2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.